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Summary
Carbon monoxide (CO) suppresses proinflammatory
responses in macrophages reacting to LPS. We hy-
pothesize that CO acts by inducing a molecule(s)
that suppresses the inflammatory response to subse-
quent stress. Exposure of macrophages to CO alone in
vitro produced a brief burst of mitochondrial-derived
ROS, which led to expression of PPARg. PPARg ex-
pression proved essential for mediating the anti-
inflammatory effects of CO. Blocking the CO-mediated
increase in ROS generation prevented PPARg induc-
tion, and blocking PPARg prevented CO’s anti-inflam-
matory effects. In a model of acute lung injury in mice,
CO blocked expression of Egr-1, a central mediator of
inflammation, and decreased tissue damage; inhibi-
tion of PPARg abrogated both effects. These data
identify the mitochondrial oxidases as an (perhaps
the) initial cellular target of CO and demonstrate that
CO upregulates expression of PPARg via the mito-
chondria, which assures that a subsequent stress
stimulus will lead to a cytoprotective as opposed to
a proinflammatory phenotype.
Introduction
Pretreatment of cells or animals with low concentrations
of carbon monoxide (CO) exerts anti-inflammatory ef-
fects in a number of models (Otterbein et al., 2000;
Sarady et al., 2004; Fujita et al., 2001; Otterbein et al.,
2003a; Zuckerbraun et al., 2003). As an example, macro-
phages mount a proinflammatory response to LPS; with
CO treatment initiated either before or after LPS (Otter-
bein et al., 2000; Sarady et al., 2004), the proinflamma-
tory response is suppressed and the production of
*Correspondence: lotterbe@bidmc.harvard.edu
5 These authors contributed equally to this work.IL-10, an anti-inflammatory cytokine, is boosted. A sig-
nificant body of knowledge has been gained about the
signaling pathways involved in these effects. What has
not been investigated is whether CO exposure alone
modulates the molecular machinery of macrophages
so that a subsequent stress stimulus will elicit an anti-in-
flammatory as opposed to a proinflammatory response.
We hypothesize that CO mediates its effects by upregu-
lating a molecule (or molecules) in the macrophage that,
by virtue of its presence, modulates the later molecular
response to a stress stimulus. To gain insight into differ-
ential gene expression patterns, we initially employed
gene chip technology and then related candidate genes
to their involvement in modulating the inflammatory re-
sponse. One of the genes that emerged was peroxisome
proliferator-activated receptor-g (PPARg). PPARg is
a nuclear hormone receptor expressed in monocytes
and macrophages, where it plays a critical role in regu-
lating the expression of genes involved in inflammatory
signaling (Welch et al., 2003; reviewed in Delerive
et al., 2001; Gelman et al., 2005). The molecular mecha-
nisms by which PPARg dampens the macrophage in-
flammatory responses are thought to be mediated by in-
hibition of expression of proinflammatory molecules
such as TNFa, IL-6, IL-1b, IP-10, and iNOS (Ricote
et al., 1998; Welch et al., 2003).
Given that CO is known to bind to oxidases (hemopro-
teins) in the mitochondria, we examined the effects of
CO on the generation of reactive oxygen species
(ROS). We show that exposure to CO leads to a rapid
and brief burst of ROS from the mitochondria that di-
rects the subsequent upregulation of PPARg. Both
events prove essential for the anti-inflammatory effects
of CO both in vitro and in vivo. These findings provide us
with our first understanding of the early cellular re-
sponse to CO that is involved in the mediation of its
anti-inflammatory effects.
Results
CO Suppresses LPS-Induced Egr-1 mRNA and
Protein Expression via PPARg
Preliminary microarray studies (Figures S2 and S3 and
Table S1) showed that CO strongly suppressed Egr-1
mRNA and protein expression in macrophages treated
with 100 ng/ml of LPS as compared to cells stimulated
in the absence of CO (Figures 1A–1C). CO exposure
also prevented Egr-1/DNA binding in nuclear extracts
of LPS-treated cells (Figure 1D). We evaluated a poten-
tial role for PPARg, which suppresses ischemia-induced
Egr-1 in alveolar macrophages, in the anti-inflammatory
effects of CO (Okada et al., 2002). Inhibition of PPARg
with its selective inhibitor GW9662 added prior to CO
did not affect Egr-1 expression in LPS-stimulated cells.
However, blocking of PPARg did block the suppressive
effect of CO seen in the absence of the PPARg inhibitor
(Figure 1E). Similarly, experiments using siRNA to spe-
cifically inhibit PPARg (Figure 1F and Figure S1) demon-
strated that the ability of CO to block Egr-1 induction
was PPARg dependent. Figure 1G depicts the
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602Figure 1. CO Inhibits Egr-1 Expression/Func-
tion via PPARg in Macrophages
(A) RAW cells were stimulated with LPS (100
pg/ml) in the presence or absence of 250
ppm CO. Egr-1 mRNA was analyzed by RT-
PCR. One representative agarose gel is
shown.
(B) Quantitative densitometric data are ex-
pressed as Egr-1/b-actin mRNA levels. Data
are mean (n = 3) 6 SD (*p < 0.05 versus LPS).
(C) Egr-1 protein expression. b-actin demon-
strates equal protein loading.
(D) EMSA for Egr-1 on nuclear extracts of
cells treated with CO or air followed by stim-
ulation with LPS for 1 hr. The left-most lane is
Egr-1-free probe. Migration of the band cor-
responding to the Egr-1-DNA complex is indi-
cated on the right. Egr-1 specificity of the
protein-DNA interaction was shown by com-
petition experiments in which a 100-fold mo-
lar excess of unlabeled Egr-1 probe obliter-
ated the appearance of the gel shift band
(marked as ‘‘competitor: +’’).
(E) RAW cells were pretreated with GW9662
(2 mM) followed by treatment with or without
CO. LPS was then added and expression as-
sessed by Western blotting. The blot is repre-
sentative of four independent experiments.
(F) To inhibit endogenous PPARg expression,
RAW cells were transfected with a PPARg-
specific siRNA (see Figure S1 for specificity
and sequences tested). PPARg protein levels
were determined 48 hr later by Western blot-
ting. The blot is representative of three inde-
pendent experiments.
(G) RAW cells were transfected with control
(open bars) or PPARg-specific siRNA (filled
bars) followed by a 3 hr pretreatment with or
without CO 48 hr later. LPS was then added,
and expression analyzed by real-time-PCR.
Quantitation of siRNA experiments is ex-
pressed as Egr-1 mRNA normalized to b-ac-
tin and nonstimulated siRNA-transfected
controls. Data are mean (n = 3) 6 SD (*p <
0.05 versus LPS/ctrl-siRNA; ns, not signifi-
cant versus LPS/PPARg-siRNA).
(H) Differentiated BMDM from PPARg-loxP mice (B6.129-Ppargtm2Rev/J) or BMDM isolated from wild-type controls (open bars) were infected with
adeno-Cre recombinase for 36–48 hr. Efficiency of infection was determined with Adeno-EGFP, and confirmation of recombination was per-
formed by semiquantitative RT-PCR-detecting floxed-out exons 1 and 2 (w300 bp; upper panel) in the adeno-Cre-treated cells. LPS was
then added to the media in the presence or absence of CO (250 ppm), and Egr-1 expression was measured 1 hr later by RT-PCR as described
in (G). Note that CO blocked LPS-induced Egr-1 in control-infected BMDM but was not able to block in those cells infected with adeno-Cre
recombinase where PPARg expression was disrupted through Cre-mediated recombination of the PPARg floxed exons 1 and 2.quantitative analyses of the siRNA experiments. The
siRNA did not inhibit LPS-induced Egr-1. The role of
PPARg in mediating the CO effects was further investi-
gated with aCre/lox system. Bone marrow derived mac-
rophages were prepared as described in Experimental
Procedures from wild-type and PPARg-loxP mice and
infected with an adenovirus expressing Cre recombi-
nase. Recombination and knockdown was verified in
these cells, and >95% efficiency of infection was ob-
served (Figure 1H, upper panels). These cells were
treated with LPS in the presence and absence of CO,
and Egr-1 expression was measured by real-time PCR.
As shown in Figure 1H, LPS induced a significant in-
crease in Egr-1 expression in Ad-Cre-treated wild-type
cells, which was blocked in the presence of CO. In the
Ad-Cre-infected PPARg-loxP cells in which PPARg
was knocked down, CO was unable to inhibit LPS-in-duced Egr-1. These experiments confirm the ones using
siRNA as well as those using the selective PPARg inhib-
itor. These data demonstrate that the ability of CO to
suppress Egr-1 expression in response to LPS is depen-
dent on the activation of PPARg.
CO Increases Nuclear PPARg that Inhibits LPS-
Induced Elk-1 Activation
Exposure of RAW cells to CO for 2–4 hr resulted in an in-
crease in nuclear PPARg demonstrated by immunofluo-
rescence staining, Western blotting, and reporter as-
says (Figures 2A–2C). Because LPS induces Egr-1
activation via phosphorylation of the transcription factor
Elk-1 (Guha et al., 2001), we investigated whether
PPARg modulates LPS-induced Elk-1 phosphorylation.
Phosphorylation of Elk-1 was barely detectable in un-
treated cells; addition of LPS resulted in a rapid increase
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hibited an average of 36% in the presence of CO (Fig-
ures 3A–3C). Inhibition of PPARg by GW9662 did not
affect LPS-induced nuclear Elk-1 phosphorylation; how-
ever, the inhibitory effect of CO on Elk-1 phosphoryla-
Figure 2. CO Increases Nuclear PPARg Expression and Activity
(A) RAW 264.7 cells were exposed to air or CO (4 hr) and immuno-
stained for PPARg. The image is representative of three experiments
with similar results.
(B) Left, RAW cells were treated with CO for the indicated times, and
nuclear protein analyzed by Western blotting for PPARg expression.
Right, quantitative densitometric data expressed as PPARg/TFIIB
expression relative to untreated (air) control cells. Data are pre-
sented as mean (n = 3) 6 SD (p < 0.05).
(C) RAW cells were transfected with the AOX -TK plasmid and ex-
posed to CO (250 ppm) or ciglitazone as a positive control (10 mM)
for 15 hr. Luciferase activity was normalized to total protein extract
and expressed as a percentage of untreated (control) cells. Note that
CO-evoked PPARg reporter gene activation similar to ciglitazone.
Data represent mean (n = 4) 6 SD. Graph is representative of three
independent experiments.tion was reversed when PPARg was inhibited (Figures
3B and 3C), consistent with a role for PPARg in the CO
effects rather than in the response to LPS.
CO Inhibits Expression of Egr-1-Dependent
Procoagulant Genes In Vitro in a PPARg-Dependent
Manner
To extend our findings of the suppressive effect of CO
and PPARg on Egr-1 expression, we examined mRNA
levels of tissue factor (TF) and plasminogen activator in-
hibitor-1 (PAI-1), two Egr-1-dependent genes that are in-
volved in disseminated intravascular coagulation (Yan
et al., 2000; Pawlinski et al., 2003). These assays were
performed at times of peak Egr-1 protein expression/
function (i.e., 60–240 min) (Figure 4A). The suppressive
effects of CO on PAI-1 induced by hypoxia have previ-
ously been reported (Fujita et al., 2001), yet the cellular
mechanisms by which this occurred were not eluci-
dated. TF protein was undetectable regardless of the
absence or presence of CO in resting macrophages
(Figure 4B). Addition of LPS strongly increased TF ex-
pression, which was significantly suppressed (by
72.7%, 57.1%, and 51.9% after 5, 9, and 15 hr, respec-
tively) (Figure 4B) in cells exposed to CO. To investigate
the role of PPARg in CO/LPS-modulated TF expression,
we pretreated RAW cells with the selective PPARg
Figure 3. CO Inhibits Elk-1 Activation via PPARg
(A) RAW cells LPS 6 CO. Cells were fixed and stained for phospho-
Elk1 expression. The image is representative of three experiments
with similar results.
(B) RAW cells were treated with GW9662 6 CO. LPS was then
added, and nuclear protein isolated and analyzed for phospho-
Elk1 by Western blotting.
(C) Quantitative densitometric data are expressed as p-Elk-1/TFIIB
expression relative to LPS-treated cells. Data represent mean
(n = 3) 6 SD (* and #, p < 0.05 versus LPS and CO/LPS/GW9662).
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Genes by CO: Role of PPARg
(A and B) GeneChip data (see Supplemental
Data) were examined for known Egr-1 re-
sponsive genes. Expression levels are ex-
pressed as ratio of CO + LPS versus LPS.
The scale at the figure bottom denotes fold
changes.
(B) TF protein expression of LPS-activated
RAW 264.7 cells was determined with
a two-stage clotting assay as described in
the Experimental Procedures. Data represent
mean (n = 4) 6 SD (p < 0.05 versus LPS).
(C) RAW cells were treated with the PPARg
inhibitor GW9662 or vehicle (DMSO) 6 CO
(250 ppm). LPS was then added, and samples
analyzed for TF expression. Results repre-
sent percent TF expression versus control
(Air) samples. Data represent mean (n = 4) 6
SD (* and #, p < 0.05 versus LPS and CO/
LPS/GW9662).
(D) RNA profiling of ctrl-siRNA (left panel) or
PPARg siRNA (right panel) transfected RAW
264.7 cells with LPS (10 ng/ml) in the absence
or presence of CO plotting 26 genes downre-
gulated at least 2-fold in the ctrl-siRNA-
treated cells that were subsequently reversed
to control-LPS values in PPARg-siRNA-
treated cells. Genes are represented by col-
ored lines according to their expression level.
Results represent normalized mean fluores-
cence from duplicate experiments of each
treatment group. A summary of significant
differences are presented in Table S3. Com-
plete GeneChip datasets are available online
as GEO entry GSE1906: http://www.ncbi.nlm.
nih.gov/projects/geo/.inhibitor GW9662 prior to LPS or to CO/LPS. GW9662
did not affect LPS-induced TF expression in the ab-
sence of CO, whereas the CO-mediated suppression
of TF expression was significantly reversed (Figure 4C).
CO also suppressed LPS-induced PAI-1 protein expres-
sion (Figures S4A and S4B), and inhibition of PPARg ab-
rogated the CO-mediated suppression (Figure S4C). In
order to explore whether these results were specific
for a few genes (TF, Egr-1) or reflected a widespread re-
quirement for PPARg to mediate the anti-inflammatory
effects of CO, we performed additional RNA profiling
to analyze the ability of CO to inhibit gene expression
in PPARg-deficient cells. The results of duplicate micro-
array experiments performed on the Affymetrix plat-
form, comparing mRNA extracted from control and
PPARg-siRNA transfected cells treated with LPS in the
absence or presence of CO, are plotted in Figure 4D.
For each treatment, all genes exhibiting an inhibition of
more than 2-fold in the CO-treated ctrl-siRNA cells (left
panel) were compared to their counterparts in CO-
treated PPARg-siRNA cells (right panel). This broader
analysis revealed that CO-mediated inhibition was pro-
foundly impaired in cells in which PPARg was knocked
down. Approximately 50% of the genes inhibited byCO in control siRNA treated cells were not inhibited in
PPARg-siRNA knocked down cells, including known
PPARg targets such as IL-6, IP-10, and thymidylate ki-
nase family LPS-inducible member (Welch, et al., 2003)
(Figure 4D and Table S3). Thus, PPARg is broadly re-
quired for the anti-inflammatory mechanism of CO in
LPS activated macrophages.
Effect of CO on LPS-Induced Lung Injury In Vivo
We assessed whether PPARg modulates the protective
effects of CO in vivo. We chose a lung injury model for
our in vivo studies to evaluate the role of CO-induced
PPARg as the lung is a major target organ for LPS-in-
duced inflammation. Additionally, we have shown previ-
ously that CO administered either pre- or post-LPS can
limit neutrophil infiltration and tissue damage (Otterbein
et al., 2003c; Sarady et al., 2004); however, the initiating
mechanism and cellular targets by which CO had these
effects remained unclear. Figure 5A shows that CO ex-
posure (250 ppm, 6 hr) resulted in a significant expres-
sion of PPARg selectively in alveolar macrophages.
We conclude that macrophages are one of the key tar-
gets by which CO exerts its anti-inflammatory effects.
Mice given LPS showed elevated Egr-1 protein levels
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tion and lipid peroxidation (based on measurements of
MPO and MDA accumulation, respectively, in lung ex-
tracts). PPARg appeared not to be involved in these re-
sponses: administration of GW9662 did not affect Egr-1
expression or its proinflammatory consequences in re-
sponse to LPS alone. CO significantly suppressed the
LPS-mediated increase of Egr-1 (Figure 5B) as well as
the increase in MPO and MDA in the lung (Figures 5D
and 5E). We tested whether the CO effects in vivo re-
quired PPARg by administrating GW9662 to mice 30
min prior to pretreatment with CO. Inhibition of PPARg
suppressed the anti-inflammatory effects of CO. These
data indicate that CO led to a PPARg-dependent anti-
Figure 5. Effects of CO on Leukocyte Accumulation and Lung Dam-
age in Endotoxin-Treated Mice Depends on PPARg Activity
(A) Mice were exposed to CO for 6 hr. Lungs were harvested and im-
munostained for PPARg protein expression (arrows indicate posi-
tive staining macrophages). Images are representative sections
from 15–20 sections/lung from three to four individual mice/group.
Bar represents 20 mm.
(B) Mice were exposed to CO for 1 hr followed by injection of LPS.
Lungs were harvested, and Egr-1 protein expression was assessed
by Western blot. b-actin demonstrates equal protein loading.
(C) Mice were pretreated with GW9662 (5 mg/kg, i.p.) for 1.5 hr prior
to exposure to CO for 1 hr followed by injection of LPS. Lungs were
harvested, and Egr-1 protein expression was assessed by Western
blotting as in (B).
(D and E) Pulmonary neutrophil sequestration and tissue lipid perox-
idation was measured by MPO and MDA accumulation, respec-
tively. Mice were pretreated 30 min with GW9662 and then placed
in CO or air prior to LPS. Sixteen hours later, the lungs were har-
vested and analyzed for MPO and MDA assessment. Data represent
mean6 SD (six to eight mice/group). *p < 0.01 versus LPS, GW/LPS,
and GW/CO/LPS; #p = 0.02 versus air.inflammatory response induced by LPS (Figures 5C–
5E). Thus, the protective, anti-inflammatory effects of
CO in the lung, as in macrophages in culture, rely on
the ability of CO to increase expression of PPARg that
in turn prevents upregulation of Egr-1, a marker of the in-
flammatory response elicited by endotoxin.
CO Exposure Increases the Generation of Reactive
Oxygen Species
Exposure of RAW 264.7 macrophages to CO resulted in
a transient burst in DCF fluorescence indicative of pro-
duction of reactive oxygen species (ROS) as early as
15 min and peaking at 60 min (Figure 6A). These effects
were also observed in primary mouse alveolar macro-
phages (Figure 6A) and the human macrophage cell
line THP-1 (data not shown). To identify the source of
ROS in the cell, we depleted cells of mitochondria (Du-
ranteau et al., 1998) and then exposed them to CO. As
seen in Figure 6B, the ability of CO to generate ROS in
mitochondria deficient cells (ro) was markedly reduced
versus that generated in wild-type cells. Furthermore,
the CO-mediated increase in PPARg expression was
lost in mitochondria-deficient cells (Figure 6C). We pro-
pose that CO binds cytochrome oxidase, i.e., the heme-
containing complex IV of the mitochondria (Alonso et al.,
2003). The binding of CO to cytochrome oxidase at this
concentration does not affect cellular respiration and
ATP generation (data not shown). We tested the hypoth-
esis that this increase in ROS by CO was involved in the
upregulation of PPARg by performing two sets of exper-
iments. First, addition of the membrane-permeable anti-
oxidants superoxide dismutase and catalase resulted in
the loss of CO-induced ROS production and PPARg ex-
pression (Figure 6D). Second, treatment of cells with
Antimycin A, which selectively blocks mitochondrial
electron transport at complex III, not only effectively
abrogated CO-induced ROS and PPARg expression
(Figure 6D) but also reversed the inhibitory effect of
CO on LPS-induced Egr-1 expression (Figure 6E). We
saw similar effects if cells were treated with the alterna-
tive complex III inhibitor myxothiazol (data not shown).
We conclude that blocking electron transport at com-
plex III prevents electrons from being transferred to
complex IV to increase superoxide generation. More-
over, by providing the antioxidant enzymes, superoxide
anion and hydrogen peroxide are rapidly removed and
therefore cannot contribute to mediating the CO re-
sponse. These data suggest that the mitochondria are
at least one of the targets for CO in macrophages and
that the burst of ROS leads to the subsequent activation
of PPARg.
Discussion
The most significant findings of the present study are the
demonstration that CO alone leads to the generation of
mitochondrial ROS that, in turn, play a role as signaling
molecules to upregulate PPARg, and further, that
PPARg, at least in large measure, accounts for the
anti-inflammatory effects of CO in vitro and in vivo. By
upregulating PPARg, CO by itself alters the molecular
response machinery of the cell such that a subsequent
stress stimulus, in this case endotoxin, generates an
anti-inflammatory as opposed to the classical
Immunity
606Figure 6. CO Exposure Increases ROS Gen-
eration that Is Responsible for CO-Induced
PPARg Upregulation
(A) Kinetics of CO-induced increases in DCF
fluorescence. RAW 264.7 cells were exposed
to CO after addition of DCFH-DA. Relative
flouresence was compared to DCFH-DA-
loaded air-treated cells. PMA was used as
a positive assay control.
(B) Mitochondrial-deficient cells (ro) do not
generate ROS in response to CO. Results
represent mean 6 SD of four measurements
at each time point from three separate exper-
iments.
(C) Wild-type (wt) or mitochondrial-deficient
cells (ro) were treated with CO (250 ppm) for
4 hr, and PPARg expression was determined
thereafter. The blot is a representative image
from three separate experiments.
(D) RAW 264.7 cells were pretreated with ei-
ther antimycin A or PEG-SOD + PEG-catalase
prior to CO. Expression of PPARg was deter-
mined 4 hr later. Note that interference with
electron transport as well as the presence of
the antioxidant enzymes prevented the ability
of CO to upregulate PPARg. Blots are repre-
sentative images from three separate experi-
ments.
(E) RAW 264.7 cells were pretreated with anti-
mycin A prior to CO. LPS was then added,
and Egr-1 mRNA expression analyzed by
RT-PCR. Note that interference with electron
transport prevented the ability of CO to inhibit
LPS-induced Egr-1 expression. Data are
mean (n = 3) 6 SD (*p < 0.05 versus LPS
and CO + LPS + antimycin A).proinflammatory response. CO exposure has been
shown to induce a number of other molecules, including
NF-kB in hepatocytes (Zuckerbraun et al., 2003) and
cGMP in smooth muscle cells (Morita et al., 1997; Pey-
ton et al., 2002; Otterbein et al., 2003b). To what extent
these other molecules have a similar role in the benefits
afforded by CO remains to be elucidated. A recent report
by Reinking et al. describes a heme-containing nuclear
receptor that is responsive to gases including NO and
CO in Drosophila. They go on to suggest that this recep-
tor may function as a gas sensor that mediates intracel-
lular signaling (Reinking et al., 2005). A similar report by
Dioum et al. describes a gas-responsive PAS2 domain
transcription factor in the murine nervous system (Di-
oum et al., 2002). Whether such a factor exists in other
cell types remains to be determined. The identification
of gas-specific CO-responsive molecules supports our
findings of a role for CO as a homeostatic molecule
and emphasizes the overall importance of CO and other
gases such as nitric oxide as biological effectors in the
inflammatory system.
We focused on Egr-1, a key transcription factor for the
generation of the inflammatory response in macro-phages (Guha et al., 2001; Yan et al., 2000). Egr-1
mRNA, protein, and activity were rapidly induced by
LPS both in vitro and in vivo in the lung. Pretreatment
with CO resulted in almost complete suppression of
Egr-1 mRNA and protein expression as well as DNA
binding activity (Figure 1). These suppressive effects
of CO on Egr-1 (as well as the corresponding suppres-
sion of TF and PAI-1) were PPARg dependent: the upre-
gulation of PPARg by CO (Figure 2) was essential for
the suppression of Egr-1 by CO. Both in the in vitro
and in vivo models, the protective effect was lost with
PPARg inhibition either pharmacologically or geneti-
cally. These results reveal an important molecular target
for CO.
The inhibitory effect of CO on Egr-1 expression and
function in RAW cells resulted in a decrease in mRNA
and protein expression of Egr-1 target genes, including
TF (Figure 4). The critical effect of Egr-1 on TF expres-
sion has been shown in LPS-stimulated egr-12/2 mice
in which TF upregulation was virtually absent (Pawlinski
et al., 2003). We hypothesized that inhibition of Egr-1 ac-
tivity by PPARg could be the mechanism by which CO
exerts its repressive effect on TF transcription. Indeed,
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expression in cells exposed to CO.
A major goal in the current studies was to identify an
early cellular event (or events) stimulated by CO alone
that could explain the suppressive effects of CO on the
LPS response. Our gene chip analysis identified Egr-1
as being highly upregulated by LPS and just as signifi-
cantly downregulated by CO pretreatment before LPS.
It was known that PPARg potently regulates Egr-1
(Okada et al., 2002). Additionally, the effects of PPARg
are very similar to those of CO when examined in identi-
cal models, i.e., both have anti-inflammatory and anti-
proliferative effects (Chawla et al., 2001; Otterbein
et al., 2003a; Okada et al., 2002; Simonin et al., 2002;
Jiang et al., 1998; Theocharis et al., 2004). This sup-
ported our hypothesis that CO might function in part
via PPARg. The data presented here show that PPARg
is upregulated in macrophages in vitro and in vivo before
the addition of LPS, presumably conditioning the cells to
respond in an anti-inflammatory fashion to protect the
cell and limit lung leukocyte infiltration and tissue dam-
age. We speculate that similar mechanisms are opera-
tive in other inflammatory models, such as hyperoxia
and ischemia/reperfusion-induced lung injury, where
CO has been shown to be protective (Zhang et al.,
2003; Otterbein et al., 2003a; Fujita et al., 2001; Song
et al., 2003).
Since CO is most likely to bind to a hemoprotein, it is
unlikely that PPARg, which does not contain a heme
moiety, is the initial molecular contact for CO. While
searching for a molecular target that might be involved
upstream of PPARg, we noted that CO rapidly stimu-
lates a transient and relatively low intensity oxidative
burst originating from the mitochondria. The resultant
ROS are involved in the subsequent induction of PPARg.
To assess whether CO might increase expression of
PPARg ligands and thus regulate PPARg activation,
we transiently cotransfected a chimeric fusion plasmid
containing the PPARg ligand binding domain (LBD)
fused to the Gal4 DNA binding domain (pCMV-Gal4-
PPARg LBD) and a reporter plasmid containing the lucif-
erase gene under regulation by four Gal4 DNA binding
elements (pFR-Luc; kind gifts from J. Flier, Department
of Endocrinology, Beth Israel Deaconess Medical Cen-
ter, Boston, MA) (Schopfer et al., 2004). Exposure to
known ligands such as troglitazone resulted in the ex-
pected increase in luciferase (>7-fold) as expected,
while no change in luciferase was observed in cells ex-
posed to CO (data now shown). We conclude from these
experiments that increased ligand generation is not
a mechanism by which CO modulates PPARg expres-
sion and activity. The upregulation of PPARg by the ox-
idative burst occurs very quickly in response to CO. We
see increases in ROS generation as early as 5 min of ex-
posure (data not shown). Whether other mechanisms
exist that would also explain how CO facilitates accumu-
lation of PPARg and thus suppresses Egr-1 remains to
be elucidated. Nuclear-cytoplasmic shuttling of PPARg
as well as modulation of the proteasome pathway
(which regulates PPARg function) may also be involved
(Cheng et al., 2004; Kelly et al., 2004).
There is accumulating evidence of a role for PPARg in
the regulation of pro- and anti-inflammatory transcrip-
tion factors, including Egr-1, NF-kB, SP-1, and NF-AT(Shi et al., 2002; Yang et al., 2000; Cheng et al., 2004;
Kelly et al., 2004). Consistent with our finding that the in-
hibitory effects of CO on LPS-induced Egr-1 expression
are acting via PPARg activation is our observation that
inhibition of PPARg reversed the CO-inhibitory effect
on activation of Elk-1, which mediates Egr-1 gene ex-
pression (Shi et al., 2002; Okada et al., 2002). There are
previous reports on the relationship of PPARg to Elk-1
and Egr-1 (Guha et al., 2001). Overexpression of wild-
type PPARg in human synovial fibroblasts suppressed
transcriptional activity of a luciferase reporter construct
containing putative Egr-1 binding sites (Sugawara et al.,
2002); the inhibition of luciferase activity was further en-
hanced in the presence of the PPARg agonist 15dPGJ2
(Sugawara et al., 2002). PPARg ligands were also re-
ported to inhibit hypoxia-induced Egr-1 expression in
mononuclear phagocytes (Okada et al., 2002).
CO may also suppress Egr-1 by mechanisms inde-
pendent of PPARg as reversal by the selective inhibitor
is not complete. Theoretical possibilities include in-
volvement of the ERK-1/2 MAPK pathway, cGMP or
NAB2, which is an inducible corepressor of Egr-1 (Shi
et al., 2002; Fujita et al., 2001; Chen et al., 2003; Lucerna
et al., 2003). However, CO does not modulate ERK-1/2
activation or increases in cGMP in RAW cells (Otterbein
et al., 2000), arguing against the possibility that CO in-
hibits Egr-1 expression via blockade of ERK-1/2. Like-
wise, NAB2 mRNA levels in LPS- and CO/LPS-treated
RAW macrophages were similar (data not shown), mak-
ing it less likely that CO acts through NAB2. We have
previously documented the involvement of p38 MAPK
in CO-mediated suppression of vascular smooth muscle
cell proliferation as well as the ability of CO to block LPS-
induced NF-kB activation in the lung (Sarady et al.,
2004). Neither of these effects has to date been linked
to PPARg. The role of p38 MAPK and the augmented ac-
tivation state of p38 MAPK induced by CO as well as the
decreased activity of NF-kB manifest themselves only
after pretreatment with CO followed by stimulation
with LPS in this model; both are either weakly or not af-
fected by CO alone during the pretreatment period (Ot-
terbein et al., 2000; Fujita et al., 2001). Further studies
will be needed to evaluate whether CO-induced PPARg
is involved in the previously reported effects of CO pre-
treatment on the response to LPS of p38 MAPK and/or
NF-kB (Otterbein et al., 2000; Sarady et al., 2004). For
the moment, we conclude that PPARg suppresses
LPS-induced Egr-1 expression by inhibiting Elk-1 acti-
vation, leaving open the possibility that this may involve
effects on p38 and NF-kB.
How the ROS burst in response to CO leads to PPARg
upregulation is unknown. The reports from Reinking and
Dioum mentioned above make clear that there are alter-
native hemoproteins that might also be involved in the
cellular response to CO or perhaps integrated into the
PPARg effects. We speculate that either a ROS-sensi-
tive intermediate is involved or that PPARg itself is di-
rectly regulated by the oxidative burst. Potential targets
for the CO-induced ROS might include modulation of the
protein phosphatases, decreased degradation of
PPARg (Hauser et al., 2000), or differential regulation
of scaffold regulatory corepressor or coactivator pro-
teins such as PGC-1, nuclear hormone receptor core-
pressor (NcoR), and silencing mediator for retinoid and
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608thyroid hormone receptors (SMRT), phosphorylation by
MAP kinases (Gelman et al., 2005), or SUMOylation
(Pascual et al., 2005). These results give support to our
model that CO at low concentrations orchestrates the
molecular machinery of the cell in a manner that will de-
termine the subsequent response to stress.
Experimental Procedures
Cell Culture
RAW 264.7 mouse peritoneal macrophages from ATCC (Rockville,
MD) and primary mouse alveolar macrophages obtained via bron-
choalveolar lavage of C57BL/6 mice were cultured in DMEM con-
taining 10% FBS and 100 mg/ml gentamicin. Cells were exposed to
2–4 hr CO (250 ppm) or air as previously described (Otterbein
et al., 2000) prior to addition of LPS (1 ng/ml E. coli serotype
O127:B8; Sigma, St. Louis, MO). GW9662 was purchased from Cal-
biochem (San Diego, CA). Antimycin A, PEG-Catalase, and PEG-
SOD were purchased from Sigma Chemical (St. Louis, MO). All
agents were used at the indicated concentrations.
Semiquantitative RT-PCR
Using the software Primer3 (Whitehead Institute/MIT Center for Ge-
nome Research; http://www.genome.wi.mit.edu/), we selected se-
quence-specific primers from the full-length published cDNA se-
quences (Table S1). Two hundred nanograms total RNA was
amplified with the One-Step RT-PCR kit (Qiagen). Reverse transcrip-
tion was carried out at 55ºC for 30 min, and HotStarTaq DNA poly-
merase was activated at 95ºC for 15 min followed by 24–27 cycles
of amplification (94ºC for 30 s, 55ºC for 30 s, and 72ºC for 60 s)
and final extension at 72ºC for 10 min. Amplified PCR products
were separated by agarose gel electrophoresis and stained with
ethidium bromide.
Real-Time PCR
Total RNA (1 mg) was reverse transcribed into cDNA by MMLV en-
zyme (Promega, Mannheim, Germany) with random heaxamers (1
mg/mg total RNA). The reaction mixture was incubated at 37ºC for
45 min followed by 15 min at 45ºC and 20 min at 70ºC. All PCRs
were performed with the SYBR Green kit (BioRad, Hercules, CA).
Primers for selected genes are listed in Table S1. By using
a Mx3000P QPCR System (Stratagene, La Jolla, CA), PCR cycling
conditions were as follows: initial denaturation at 95ºC for 10 min,
followed by 40 cycles at 94ºC for 30 s, 58ºC for 15 s, and 72ºC for
30 s and a 10 min terminal incubation at 72ºC. Sequence Detector
Software (Stratagene) was used to extract the PCR data, which
were then exported to Excel (Microsoft, Redmond, WA) for further
analysis. Expression of target genes was normalized to b-actin ex-
pression levels.
SDS-PAGE and Western Blotting
Cells and tissue lysates were separated by SDS-PAGE and blotted
as described previously (Otterbein et al., 2000; Fujita et al., 2001).
Blots were incubated with primary rabbit anti-Egr-1, mouse anti-
phospho-Elk-1 (Santa Cruz Biotechnology, Santa Cruz, CA), or rab-
bit anti-PPARg (Upstate, Lake Placid, NY). Membranes were then
washed in TTBS and visualized with HRP-conjugated antibody
against rabbit or mouse IgG and the ECL reagents (Amersham, Pis-
cataway, NJ) per manufacturer’s instructions. To confirm equal
loading, we reprobed blots with mouse monoclonal antibody target-
ing b-actin (Abcam, Inc., Cambridge, MA) or rabbit anti-TFIIB IgG.
Transfection and Transient Reporter Assays
RAW 264.7 cells were transfected in the presence of 10% FCS at 1
mg/well with the PPAR-responsive reporter plasmid p(AOX)3-TKSL
(kindly provided by C.K. Glass; Department of Medicine, University
of California, San Diego, La Jolla, CA) with Lipofectamine 2000 (ac-
cording to the manufacturer’s instructions; Invitrogen, Carlsbad,
CA). Six hours later, cells were washed and treated with CO or cigli-
tazone (BioMol, Plymouth Meeting, PA). After 15 hr, protein extracts
were assessed for luciferase activity (Promega, Madison, WI). Lumi-
nescence values were normalized to total protein levels and pre-sented as the percentage of luciferase activity measured with CO
or troglitizone or rosiglitazone.
PPARg-Knockdown Assays
RAW 264.7 cells were plated in 12-well plates at a density of 1.5 3
105 cells/well. On the next day, the cells were transfected with 100
nM PPARg-SMARTpool reagent (Dharmacon) with Lipofectamine
2000. Four siRNA sequences were tested of which one was used
for experimentation (#2; see Figure S1 for sequence and method).
For PPARg knockdown assays, the preannealed oligo (Dharmacon;
50-GAC AUG AAU UCC UUA AUG AUU -30; bp 874–893 of GenBank
NM_011146) was used at 100 nM. The medium was replaced 36 hr
later, and cells were stimulated with LPS another 12 hr later in the ab-
sence or presence of CO. RT-PCR was employed to assess Egr-1
and b-actin mRNA levels. A GC-control oligo (catalog number, D-
001206-01-05; target sequence, 50-NNATGAACGTGAATTGCTCAA-
30; Dharmacon) was used at the same concentration.
DCF Fluorescence as a Measure of Intracellular
Production of ROS
RAW 264.7 macrophages were incubated with air or CO (250 ppm)
for 5–60 min. Cells were loaded with DCFH-DA (Molecular Probes,
Eugene, OR; 5 mM) 15 min prior to harvest time point. Cells were
then washed and resuspended in FACS buffer (PBS + 1% FBS),
and fluorescence was measured as previously described (Duran-
teau et al., 1998).
Generation of Mitochondrial-Deficient ro Cells
RAW 264.7 cells were grown as above and supplemented with 50
ng/ml ethidium bromide (EtBr), 100 mg/ml pyruvate, and 50 mg/ml uri-
dine. EtBr treatment was suspended after 14 doubling times (w21
days). Cells were then tested for their ability to survive ‘‘ro selection
media’’ consisting of DMEM/10% FBS plus pyruvate and pyrimi-
dines that confirmed auxotrophy. Surviving colonies were subcul-
tured in ro selection media.
Immunostaining
Cells grown on coverslips were washed, fixed with 4% paraformal-
dehyde, permeabilized with Triton-X 100, and blocked with goat se-
rum. Expression of PPARg and p-Elk-1 were detected with anti-
bodies described above and visualized with Alexa-594 conjugated
goat anti-mouse or goat anti-rabbit antibodies (Molecular Probes).
Nuclei were visualized with Hoechst 33258 (Sigma). Pictures were
captured with a Zeiss Axio Microscope (Carl Zeiss Optics, Jena,
Germany). PPARg was detected in frozen lung sections with rabbit
anti-PPARg polyclonal Ab (Upstate, Inc., Waltham, MA). Eight to
ten images from each animal were captured.
Electrophoretic Mobility Shift Assays
Nuclear extracts were prepared according to a modified Shapiro’s
method (Shapiro et al., 1988). Gel-purified oligonucleotides (Oligos
Etc., Wilsonville, OR) containing the consensus binding site for
Egr-1 (50-GGATCCAGCGGGGGCGAGCGGGGGCGA-30 and 30-
CCTAGGTCGCCCCCGCTCGCCCCCGCT-50) were labeled with
32P ATP and used for EMSA. Electrophorestic mobility shift assays
(EMSA) reactions were assembled and run as described previously
(Usheva and Shenk, 1996).
Measurement of Tissue Factor Activity
Tissue factory (TF) activity was measured with a two-stage chromo-
genic reaction as described previously (Kopp et al., 1998).
Adenoviral Infections of Bone-Marrow-Derived Macrophages
Bone-marrow-derived macrophages (BMDM) were isolated from
B6.129-Ppargtm2Rev/J mice (Jackson Laboratory, Bar Harbor, ME)
and differentiated as previously described (Xiong et al., 2004).
Recombinant adenoviral stocks were obtained from the Gene
Transfer Vector Core facility at the University of Iowa College of
Medicine (Iowa City, IA). Infections (Cre recombinase and control vi-
rus) were performed with a concentration of 25 MOI/cell. Infections
were performed on day 4 post harvest as previously described
(Brouard et al., 2000). All experiments were performed on day 5–6.
To assess Cre activities in transduced PPARg lox-BMDMs, total
RNA was extracted 3 days posttransduction and subjected to
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609semiquantitative RT-PCR as described (Hevener et al., 2003). Two
oligonucleotides located in exons A1 and A4 of the PPARg1 gene
were designed to recognize the full length (700 bp) and recombined
messages (300 bp): GTCACGTTCTGACAGGACTGTGTGAC (50-) and
TATCACTGGAGATCTCCGCCAACAGC (30-).
Endotoxin-Induced Acute Lung Injury in Mice
Male C57BL/6J mice from Jackson labs were housed at the Univer-
sity of Pittsburgh or Beth Israel Deaconess Medical Center Animal
Facilities and allowed to acclimate 1 week prior to experimentation.
The protocol was approved by the University of Pittsburgh and Beth
Israel Deaconess Medical Center Animal Care and Use Committees.
On the day of experimentation, mice were treated with GW6996 (5
mg/kg, i.p.) 30 min prior to being placed in CO (250 ppm) (Otterbein
et al., 2000) or maintained in room air. One hour thereafter, the mice
were administered LPS (1 mg/kg, i.p.) and returned to room air for
the duration of the experiment. Sixteen hours post LPS, the animals
were sacrificed, and the lungs harvested and snap frozen in liquid
N2. Lung tissue was divided and processed for protein determina-
tion and measurements of malondialdehyde (MDA) and myeloperox-
idase (MPO) with kits per manufacturer’s instructions (R&D, Minne-
apolis, MN, and Oxidoresearch, Portland, OR, respectively). Results
are expressed per mg total protein to normalize.
Statistical Analysis
Band intensities were quantified by densitometric analyses with
a MultiImage Densitometer and ChemiImage 5500 software (Alpha
Innotech, San Leandro, CA). Statistical analysis was made by using
Student’s t test. Results were considered statistically significant at
p < 0.05.
Supplemental Data
Supplemental Data include the method for cRNA synthesis and gene
expression profiling as well as additional supporting figures and ta-
bles referenced within the text. These are available at http://www.
immunity.com/cgi/content/full/24/5/601/DC1/.
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